CD274 and hepatocellular carcinoma: While results of ICI monotherapy have been disappointing so far (15–17), the recently presented and published phase III IMbrave150 study comparing the PD-L1 inhibitor atezolizumab plus bevacizumab versus sorafenib monotherapy as front-line treatment approach for advanced HCC patients has established a new standard of care (18–20).